JP2025508832A5 - - Google Patents
Info
- Publication number
- JP2025508832A5 JP2025508832A5 JP2024550167A JP2024550167A JP2025508832A5 JP 2025508832 A5 JP2025508832 A5 JP 2025508832A5 JP 2024550167 A JP2024550167 A JP 2024550167A JP 2024550167 A JP2024550167 A JP 2024550167A JP 2025508832 A5 JP2025508832 A5 JP 2025508832A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- subject
- administration
- fraction
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313932P | 2022-02-25 | 2022-02-25 | |
| US63/313,932 | 2022-02-25 | ||
| US202263393212P | 2022-07-28 | 2022-07-28 | |
| US63/393,212 | 2022-07-28 | ||
| US202263420782P | 2022-10-31 | 2022-10-31 | |
| US63/420,782 | 2022-10-31 | ||
| US202263424210P | 2022-11-10 | 2022-11-10 | |
| US63/424,210 | 2022-11-10 | ||
| US202363440304P | 2023-01-20 | 2023-01-20 | |
| US63/440,304 | 2023-01-20 | ||
| PCT/US2023/013836 WO2023164143A1 (en) | 2022-02-25 | 2023-02-24 | Dosing regimens for mitigation of cytokine release syndrome with odronextamab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508832A JP2025508832A (ja) | 2025-04-10 |
| JP2025508832A5 true JP2025508832A5 (https=) | 2026-02-27 |
Family
ID=85778997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550167A Pending JP2025508832A (ja) | 2022-02-25 | 2023-02-24 | サイトカイン放出症候群の軽減のための投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272118A1 (https=) |
| EP (1) | EP4482524A1 (https=) |
| JP (1) | JP2025508832A (https=) |
| KR (1) | KR20240167457A (https=) |
| CN (1) | CN119156226A (https=) |
| AU (1) | AU2023224098A1 (https=) |
| CA (1) | CA3244791A1 (https=) |
| IL (1) | IL315011A (https=) |
| MX (1) | MX2024010292A (https=) |
| TW (1) | TW202400228A (https=) |
| WO (1) | WO2023164143A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CA3110513A1 (en) * | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| TW202135860A (zh) | 2019-12-10 | 2021-10-01 | 美商再生元醫藥公司 | 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
-
2023
- 2023-02-23 TW TW112106608A patent/TW202400228A/zh unknown
- 2023-02-24 CN CN202380035668.7A patent/CN119156226A/zh active Pending
- 2023-02-24 WO PCT/US2023/013836 patent/WO2023164143A1/en not_active Ceased
- 2023-02-24 IL IL315011A patent/IL315011A/en unknown
- 2023-02-24 US US18/114,057 patent/US20230272118A1/en active Pending
- 2023-02-24 EP EP23713991.0A patent/EP4482524A1/en active Pending
- 2023-02-24 CA CA3244791A patent/CA3244791A1/en active Pending
- 2023-02-24 KR KR1020247032140A patent/KR20240167457A/ko active Pending
- 2023-02-24 AU AU2023224098A patent/AU2023224098A1/en active Pending
- 2023-02-24 JP JP2024550167A patent/JP2025508832A/ja active Pending
-
2024
- 2024-08-21 MX MX2024010292A patent/MX2024010292A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| US8734799B2 (en) | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer | |
| JP2022050618A5 (https=) | ||
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| EP2218461A1 (en) | CD40 antibody formulation and methods | |
| JP2023524149A5 (https=) | ||
| CN111629788A (zh) | 用拮抗性抗-pd-1抗体治疗癌症的方法 | |
| JP2021528423A5 (https=) | ||
| AU2017219596B2 (en) | Chimeric canine anti-CD20 antibody | |
| JP2023544407A5 (https=) | ||
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| JP2021130668A (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP2024534602A5 (https=) | ||
| JP2021512107A5 (https=) | ||
| JP2021501217A (ja) | 同種キメラ抗原受容体ｔ細胞投与のための方法および組成物 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JP2022541591A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| MX2011003335A (es) | Composicion para tratar enfermedad. | |
| JP2022502399A (ja) | がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ | |
| JP2025509567A5 (https=) | ||
| JP2022513029A5 (https=) | ||
| JP2025502061A5 (https=) | ||
| CA3227172A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 |